Novo Nordisk raised its 2026 financial outlook after the newly launched Wegovy pill delivered stronger-than-expected sales, a major boost for the Danish drugmaker. The oral formulation of the blockbuster weight-loss drug outperformed internal forecasts, sending shares higher in early trading.
The pill version marks a strategic expansion of Novo Nordisk’s GLP-1 portfolio, which has already generated billions in revenue through injectable versions. A convenient oral option could significantly broaden the addressable market by appealing to patients who avoid injections.
The company did not disclose specific sales figures for the pill in its preliminary update. The improved guidance suggests management sees sustained demand for the oral formulation, though analysts will await full quarterly details for precise numbers.
Investors reacted positively, with the stock climbing on the news. The raised outlook signals confidence that the oral Wegovy can capture market share, intensifying competition with Eli Lilly and other drugmakers racing to develop oral GLP-1 therapies.
Some analysts caution that manufacturing scale-up for oral GLP-1 drugs remains complex, and long-term patient adherence data is still limited. The full earnings report will provide deeper insight into profitability and production costs.